Business

Cannara Reports Q1 Fiscal 2026 Results, Delivers New Record Financial Results, Extends Market Share Gains and Advances Disciplined Expansion Strategy

New Record Financial Results:  Total revenues of $30.1 million, gross profit before fair val...

articleCannara Biotech, Inc.January 26, 20264/company/cannara-biotech-inc-1/news/cannara-reports-q1-fiscal-2026-results-delivers-new-record-financial-results-extends-market-share-gains-and-advances-disciplined-expansion-strategy
Cannara Reports Q1 Fiscal 2026 Results, Delivers New Record Financial Results, Extends Market Share Gains and Advances Disciplined Expansion Strategy

About this update from Cannara Biotech, Inc.

[{"type":"text","content":"Cannara Reports Q1 Fiscal 2026 Results, Delivers New Record Financial Results, Extends Market Share Gains and Advances Disciplined Expansion Strategy\nNew Record Financial Results: Total revenues of $30.1 million, gross profit before fair value adjustments of $13.5 million or 45% and Adjusted EBITDA of $8.8 million1, supported by operating cash flows of $8.0 million and free cash flow of $3.3 million2.Extends Market Share Gains: Estimated national retail market share reached 4.1% in Q1 2026, up from 3.8% in Q4 2025, driven by strong momentum across key provinces, including Québec, where Cannara ranked #1 by December 2025 following the successful vape launch, and continued growth in Ontario, Canada’s largest market3.Disciplined Expansion Strategy: Valleyfield’s new processing center remains on budget and on track for completion in Fiscal 2026, while the Company advances the fit-out of three additional grow zones to be cultivation-ready at the start of Fiscal 2027 to support anticipated demand.Annual General and Special Meeting: scheduled for January 29, 2026, at 11:00 a.m. EST. All financial results are reported in Canadian dollars, unless otherwise stated. MONTREAL, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at affordable prices with two mega facilities based in Québec spanning over 1,600,000 sq. ft., today announced its financial and operating results for the fiscal quarter ended November 30, 2025. The condensed interim consolidated financial statements and related notes thereto and the accompanying Management’s Discussion and Analysis can be accessed by visiting the Company’s website at investors.cannara.ca, or by accessing the Company’s SEDAR+ profile at www.sedarplus.ca. The Company’s latest investor presentation is available at www.cannara.ca/investors/investor-deck/. Management Commentary: “Our continued market share expansion in Q1 2026 reflects the strength of our brands and our disciplined approach to growth,” said Zohar Krivorot, Founder and Chief Executive Officer of Cannara. “We achieved our highest quarterly national ret...

More updates from Cannara Biotech, Inc.